Result of bifurcated devices to protect the internal iliac in aorto-iliac aneurysms

Original title: Endovascular Treatment of Aorto-iliac Aneurysms: Four-year Results of Iliac Branch Endograft. Reference: G. Pratesi et al. Eur J Vasc Endovasc Surg. 2013 Jun;45(6):607-9.

Iliac bifurcated devices have proven to be effective in treating common iliac aneurysms but the findings are based on small series, generally from a sole center experience. This multicenter registry included 85 patients with aorto-iliac aneurysms who received bifurcated devices, (most of them, Zenith Bifurcated Iliac sidebranch, Cook, Bloomington, IN, USA). Technical success was achieved in 98.7% with no perioperative mortality. The only case that could not be implanted was probably due to a very challenging anatomy.

During the first 30 days only a single occlusion of iliac branch was observed and at follow-up CT scan, three patients (3.7%) had distal type I endoleak. These patients were managed conservatively with strict surveillance protocol but thus far showed no sac growth. At follow-up (20.4 ± 15.4), seven unrelated deaths occurred leaving an estimated 24-month survival of 89.5% and 76.7% after 48 months. During follow-up there were no aneurysm-related deaths, need for conversion to conventional surgery or aneurysmatic rupture. No new branch thrombosis was registered.  

Seven patients (8.6%) progressed with buttock claudication, six of them were bilateral iliac aneurysms cases where one hypogastric was protected with a bifurcated branch and the other was embolized. The symptoms were always confined to the side of the embolized hypogastric and did not improve with time. 

Conclusion:

Iliac bifurcated devices were effective in preserving the internal iliac artery implant in the context of an abdominal aortic stent. This represents a valid technique in the case of bilateral iliac aneurysms. 

Commentary:

All patients who developed a distal type I endoleak had an ectatic internal iliac artery. Perhaps the compromise of this artery by the common iliac aneurysm should be considered as a limitation of the technique.

SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...